Trial Profile
A Randomised, Double-Blind, Placebo Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics of Hemay005 in Healthy Subjects
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 02 Jun 2020
Price :
$35
*
At a glance
- Drugs Mufemilast (Primary)
- Indications Psoriasis
- Focus Adverse reactions
- Sponsors Tianjin Hemay Biotech
- 29 Sep 2018 Status changed from not yet recruiting to recruiting.
- 02 Jul 2018 New trial record